Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Transplanting adult ALL patients

ALL Assembly 2018

Published: 18 Oct 2018

Views: 1394

Rating:

Save

Prof Sebastien Giebel - The Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland

Prof Sebastien Giebel talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about transplant as a method of treating ALL patients.

Prof Giebel discusses some of the issues surrounding these transplants but how it is still a majorly popular course of treatment.

Prof Giebel also considers how to treat T-cell ALL and whether or not technological advances will alter the landscape for treatment in the near future.

He goes on to say that, if a transplant is needed, recent advancements mean a donor can be found for everyone.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

The pros and cons of breast IORT and ultra hypofractionation (FR)

Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France

$The pros and cons of breast IORT and ultra hypofractionation (FR) ( Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France )$

IORT at the Asian Hospital and Medical Center

Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines

IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer